Stem cell therapy is one of the most promising frontiers in regenerative medicine, harnessing stem cells' capacity for self-renewal and multi-directional differentiation to repair damaged tissue and regulate immune function — improving symptoms and slowing progression across a range of chronic conditions.
Japan has one of the world's most well-developed regulatory frameworks for regenerative medicine. In 2014, Japan became the first country to enact the Act on the Safety of Regenerative Medicine, establishing full oversight from research through clinical application, and requiring medical institutions to submit their treatment protocols to the Ministry of Health, Labour and Welfare for approval before offering stem cell therapy — effectively safeguarding both compliance and patient safety.
This regulatory foundation has made Japan one of the most rigorous and trustworthy destinations in the world for stem cell therapy today — distinct from countries that ban commercial stem cell therapy outright, and equally distinct from unregulated gray-market providers — offering patients seeking regenerative medicine a reliable legal safeguard.
Japan became the first country in the world to enact dedicated regenerative medicine legislation
All partner clinics hold Ministry of Health, Labour and Welfare certification
Mainstream protocols use the patient's own cells, with minimal rejection risk
Japan's Act on the Safety of Regenerative Medicine requires medical institutions to obtain government approval before administering treatment; protocols are traceable and subject to oversight, with patient rights clearly protected by law.
Japan was an early mover in regenerative medicine — numerous universities and specialty institutions have accumulated over a decade of clinical data, with deep experience in techniques such as autologous adipose-derived and mesenchymal stem cell therapy.
Compliant Japanese regenerative medicine institutions must process stem cells in GMP-certified cell culture facilities, with the entire process fully documented and cell quality strictly guaranteed.
Japanese physicians develop a personalized stem cell treatment plan based on each patient's specific condition, disease type, and treatment goals — rather than offering a one-size-fits-all package.
Stem cell therapy currently has the most established body of clinical experience in the following areas
For patients with degenerative conditions such as knee or hip osteoarthritis, stem cell injections can promote cartilage repair, improve joint function, and reduce pain — well suited to patients who prefer to avoid or aren't yet ready for surgery.
For conditions such as post-stroke sequelae, spinal cord injury, and ALS (amyotrophic lateral sclerosis), stem cell therapy has shown, in some patients, an ability to improve neurological function and slow disease progression.
For conditions such as rheumatoid arthritis, Crohn's disease, and lupus, mesenchymal stem cells have immune-modulating properties that can help reduce abnormal immune responses and improve symptoms.
For patients with type 2 diabetes and related complications, stem cell therapy can help improve insulin secretion function to some degree, while offering supportive benefit for diabetes-related nerve and kidney damage.
For those seeking overall health improvement and anti-aging benefits, stem cell therapy can promote tissue renewal at the cellular level, support immune function, and improve energy levels — a key option in high-end wellness management.
For patients with chronic hepatitis, early-to-mid-stage cirrhosis, and chronic kidney disease, clinical research supports the use of stem cell therapy to help promote liver cell regeneration and slow the decline of kidney function, as a complement to conventional treatment.
* Stem cell therapy remains an emerging field of medicine, and not every condition has robust evidence-based support. MIZUHO PHARMA will honestly explain the suitability assessment during your consultation, without overpromising results.
From verifying institutional credentials to follow-up after you return home, we ensure professionalism and safety at every step
We rigorously screen for institutions certified under the Ministry of Health, Labour and Welfare's regenerative medicine framework, verifying their registered treatment protocols to ensure every partner clinic operates within the legal regulatory system.
We help organize the patient's existing test results, translate them into Japanese, and submit them to our partner institutions, where a Japanese physician provides an initial assessment of suitability and recommends a treatment approach.
We help facilitate a detailed discussion between the patient and the Japanese physician about the treatment plan — cell source, culturing method, number of infusions, and expected outcomes — and arrange the formal appointment once confirmed.
We assist with your medical visa application and provide travel recommendations, including accommodation and transportation coordination in Japan, so you can focus fully on your treatment.
A professional medical interpreter accompanies you throughout every stage in Japan — collection, testing, and infusion — ensuring accurate communication between you and your physician down to every detail.
After you return home, we continue to track changes in your condition, help you stay in touch with your Japanese physician, and arrange follow-up visits if additional treatment sessions are needed.
From your first consultation to completed treatment, the process typically takes 6 to 10 weeks
Contact MIZUHO PHARMA and share your basic medical information. Our advisor provides a preliminary judgment on whether stem cell therapy is a good fit based on your condition, and explains the potentially suitable technical approach and expected outcomes.
Timeframe: 1–2 business daysThe patient provides existing test reports and medical records; MIZUHO PHARMA translates and organizes them, then submits them to a suitable compliant regenerative medicine institution, where a Japanese physician conducts a specialized assessment and develops a preliminary treatment plan.
Timeframe: 5–7 business daysOnce the patient confirms the treatment plan and cost, we formally book the treatment date in Japan, while simultaneously assisting with the medical visa application.
Timeframe: 1–2 weeksAfter arriving in Japan, the patient first undergoes blood tests to confirm their physical condition, followed by stem cell collection (typically from fat tissue or bone marrow). The collected cells are sent to a GMP-certified cell culture lab for expansion, a process that typically takes 2–3 weeks.
Collection completed same-day; culturing takes approx. 2–3 weeksOnce cell culturing is complete, the patient returns to Japan for the stem cell infusion. The method of administration depends on the condition — typically intravenous, with some conditions requiring localized injection. The infusion is usually completed on an outpatient basis, with same-day discharge.
Completed the same day as the infusionAfter returning home, MIZUHO PHARMA helps you record any changes in your condition and follows up regularly, relaying the observed results back to your Japanese physician. If further treatment is needed, we can help arrange a second or additional session based on the assessed results.
Ongoing follow-up for 3–6 monthsStem cell therapy received at a compliant, certified Japanese institution is generally quite safe. Mainstream protocols in Japan use autologous stem cells (taken from the patient's own fat or bone marrow), and since the cell source is the patient's own body, the risk of immune rejection is extremely low. Common mild reactions include slight soreness at the injection site, brief low-grade fever, or mild fatigue, which typically resolve on their own within 1–3 days. Serious adverse reactions are extremely rare at compliant institutions. All of our partner institutions must operate treatment within the government-approved regulatory framework, with a complete safety monitoring system in place.
Stem cell therapy is still a relatively early-stage field of clinical application, and outcomes vary from patient to patient and condition to condition. Some patients respond significantly, while others see more limited improvement. A responsible medical institution will never make absolute promises about outcomes. During your consultation, MIZUHO PHARMA will honestly explain the current state and limitations of the evidence base, helping you set realistic expectations rather than overstating what's possible.
Mainstream regenerative medicine institutions in Japan primarily use autologous stem cells — extracted from the patient's own fat tissue (a small amount from the abdomen or thigh) or peripheral blood, then expanded in a GMP-grade laboratory before being infused back into the same patient. The main advantage of an autologous approach is the absence of immune rejection concerns. Some institutions also offer carefully screened allogeneic cord blood-derived stem cells; the appropriate choice depends on the patient's condition and disease type, as advised by the physician.
Stem cell therapy broadly falls into two categories, with the number of sessions varying by purpose:
For treating a specific condition: the number of sessions depends on the disease type and individual circumstances. Some patients see clear improvement after a single treatment; for chronic conditions, 2 to 4 courses are typically recommended, spaced 3 to 6 months apart. An autologous protocol typically requires two trips to Japan (the first for collection, the second for infusion); some institutions support single-collection cryopreservation of multiple cell batches, reducing the number of trips needed for subsequent treatments and lowering overall travel costs.
For anti-aging and wellness purposes: a complete course typically requires at least one full cycle — that is, after collecting and culturing autologous stem cells, approximately 4 infusions, spaced roughly 3 to 6 months apart. A full course generally spans 1 to 2 years, and patients can flexibly schedule each trip to Japan based on their own condition and their physician's advice.
The cost of stem cell therapy varies depending on the technical approach, cell quantity, and institution. As a general guide, a single autologous adipose-derived stem cell treatment (including collection, culturing, and infusion) typically costs approximately $14,000–$42,000 USD in medical fees, not including flights, accommodation, or other travel costs. Multi-session courses often come with a cumulative discount. (Figures are rounded USD estimates converted from the original RMB pricing.) MIZUHO PHARMA provides a detailed cost breakdown once your plan is confirmed, helping you budget thoroughly in advance.
Every patient's situation is different, and so is the right treatment plan. Contact MIZUHO PHARMA today for a professional assessment and guidance tailored to your specific situation.
